clinical trial · NCT07234032
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Pulmonary HypertensionInterstitial Lung DiseaseTreprostinil Palmitil Inhalation PowderPlacebo
brief summary
The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-311 (NCT07179380).
started
Apr 1, 2026
primary completion
Jan 22, 2031
completion
Jan 22, 2031
last updated
Nov 18, 2025
official title
A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol